Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$62.61 ▲ +1.15
(+1.87%)
MKT CAP: $9.85B • VOL: 2.01M
52W L $40 52W H $91
PCVX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$923.7M | -$569.5M | -$468.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$766.6K | -$463.9K | -$402.3K |
| EBITDA (Normalized) | -$912.7M | -$551.6M | -$468.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$655.6M | -$452.6M | -$296.8M |
| Capital Expenditures (CapEx) | $13.7M | $22.4M | $0 |
| Free Cash Flow (FCF) | -$669.3M | -$475.1M | -$296.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -27.5% | -14.9% | -11.3% |
| Cash & Short-Term Equivalents | $174.0M | $387.9M | $596.2M |
| Total Debt (Short + Long Term) | $142.7M | $92.5M | $1.27B |
| Total Stockholders' Equity | $2.69B | $3.31B | $2.60B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PCVX.